Eli Lilly Isn't Replacing Zepbound -- It's Building an Obesity Empire

Eli Lilly (NYSE: LLY) currently leads the weight loss market thanks to Zepbound. Given that analysts project this area will gain significant traction in the coming years, that may provide a strong tailwind to the drugmaker. However, the bears will point out that Eli Lilly could run into several problems. First, increased competition will erode some of its market share. Second, Eli Lilly's newer launches could cannibalize Zepbound's sales and do little to expand the market. So, the company's pipeline won't save it, or so the argument goes. In my view, the second line of reasoning is missing an important point about Eli Lilly's strategy in this market: The company is building a portfolio of differentiated therapies that will help it dominate this space over the next decade. Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool